WVE-004

WVE-004 is an investigational antisense oligonucleotide (ASO) therapy developed to target the C9orf72 gene mutation, which is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The drug works by binding to mutant C9orf72 mRNA containing hexanucleotide repeat expansions and promoting its degradation. This reduces the production of toxic dipeptide repeat proteins believed to contribute to neurodegeneration in these diseases. Preclinical studies showed that WVE-004 could significantly lower levels of pathogenic mRNA and dipeptide proteins in cell cultures and animal models. In clinical trials, intrathecal administration of WVE-004 led to robust reductions in poly(GP), a pharmacodynamic biomarker for C9orf72 activity, but did not result in meaningful clinical benefit for patients with ALS or FTD. The development program was discontinued after Phase 1b/2a due to lack of efficacy despite good safety and tolerability profiles[1][5][8][9].